60％以上卵巢癌死亡与诊断延误相关,如果患者能在肿瘤病变Ⅰ期时被发现,90％患者可以治愈。阴道声波仪、血清CA-125等检测早期卵巢癌,前者虽很敏感,但费用昂贵并且缺乏特异性,后者虽便利于初筛检查,但是敏感性不稳定。作者研究目的,确定是否多血清标记因子比单独CA-125检测可改善Ⅰ期卵巢癌的阳性检测敏感性。作者用免疫放射测定法,对46名不同组织形态的Ⅰ期卵巢癌患者和237例良性盆腔肿块病人,进行了术前血清CA-125 More than 60% of ovarian cancer deaths are associated with a delay in diagnosis, and 90% of patients can be cured if they can be found at stage I of the tumor lesion. Vaginal sounder, serum CA-125 and other detection of early ovarian cancer, although the former is sensitive, but costly and lack of specificity, the latter although it facilitates the screening test, but the sensitivity is not stable. The authors investigated the objective of determining whether multiple serum markers can improve the positive detection sensitivity of stage I ovarian cancer over CA-125 alone. The authors used immuno-radioimmunoassay in 46 patients with stage I ovarian cancer and 237 patients with benign pelvic mass with different histological types. Preoperative serum CA-125